CA2700762A1 - Pyridine derivatives for the treatment of amyloid-related diseases - Google Patents

Pyridine derivatives for the treatment of amyloid-related diseases Download PDF

Info

Publication number
CA2700762A1
CA2700762A1 CA2700762A CA2700762A CA2700762A1 CA 2700762 A1 CA2700762 A1 CA 2700762A1 CA 2700762 A CA2700762 A CA 2700762A CA 2700762 A CA2700762 A CA 2700762A CA 2700762 A1 CA2700762 A1 CA 2700762A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
pyridin
halogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2700762A
Other languages
English (en)
French (fr)
Inventor
David Ian Carter Scopes
David Christopher Horwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senexis Ltd
Original Assignee
Senexis Limited
David Ian Carter Scopes
David Christopher Horwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Limited, David Ian Carter Scopes, David Christopher Horwell filed Critical Senexis Limited
Publication of CA2700762A1 publication Critical patent/CA2700762A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2700762A 2007-10-05 2008-10-06 Pyridine derivatives for the treatment of amyloid-related diseases Abandoned CA2700762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0719559.7A GB0719559D0 (en) 2007-10-05 2007-10-05 Compounds
GB0719559.7 2007-10-05
PCT/GB2008/003359 WO2009044160A1 (en) 2007-10-05 2008-10-06 Pyridine derivatives for the treatment of amyloid-related diseases

Publications (1)

Publication Number Publication Date
CA2700762A1 true CA2700762A1 (en) 2009-04-09

Family

ID=38739251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2700762A Abandoned CA2700762A1 (en) 2007-10-05 2008-10-06 Pyridine derivatives for the treatment of amyloid-related diseases

Country Status (8)

Country Link
US (1) US20100298325A1 (zh)
EP (1) EP2205317A1 (zh)
JP (1) JP2010540609A (zh)
CN (1) CN101888877A (zh)
AU (1) AU2008306623A1 (zh)
CA (1) CA2700762A1 (zh)
GB (1) GB0719559D0 (zh)
WO (1) WO2009044160A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
GB201008209D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA3052519A1 (en) 2017-02-08 2018-08-16 Andreas Gortz Triazolethione derivatives
US20200017467A1 (en) 2017-02-08 2020-01-16 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
WO2018145934A1 (en) 2017-02-08 2018-08-16 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
WO2018145921A1 (en) 2017-02-10 2018-08-16 Bayer Aktiengesellschaft Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives
WO2019225920A1 (ko) * 2018-05-23 2019-11-28 아주대학교산학협력단 톨-유사 수용체 3/7/8/9 억제 기능이 있는 길항성 소분자 화합물 tac5 시리즈
KR102234399B1 (ko) 2018-05-23 2021-04-05 아주대학교산학협력단 톨-유사 수용체 3/7/8/9 억제 기능이 있는 길항성 소분자 화합물 tac5 시리즈
US20230348392A1 (en) 2020-05-06 2023-11-02 Bayer Aktiengesellschaft Pyridine (thio)amides as fungicidal compounds
JP2023529643A (ja) 2020-06-04 2023-07-11 バイエル、アクチエンゲゼルシャフト 新規殺真菌剤としてのヘテロシクリルピリジン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
JP2008523139A (ja) * 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 置換アミノピリジン類及びその使用
GB0608386D0 (en) * 2006-04-27 2006-06-07 Senexis Ltd Compounds

Also Published As

Publication number Publication date
JP2010540609A (ja) 2010-12-24
GB0719559D0 (en) 2007-11-14
CN101888877A (zh) 2010-11-17
WO2009044160A1 (en) 2009-04-09
EP2205317A1 (en) 2010-07-14
AU2008306623A1 (en) 2009-04-09
US20100298325A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CA2700762A1 (en) Pyridine derivatives for the treatment of amyloid-related diseases
CA2650389A1 (en) Pyrimidine derivatives for the treatment of amyloid-related diseases
WO2008107677A2 (en) Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders
CN108368046B (zh) 哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
AU2005237301A1 (en) Morpholine compounds
WO2008154083A2 (en) Compounds, compositions and methods for the treatment of synucleinopathies
EP2571872B1 (en) Compounds
FR2670491A1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
MXPA06012506A (es) Antagonistas de receptor de histamina-1.
CA3168456A1 (en) Isoindoline derivative, and pharmaceutical composition and use thereof
KR100559816B1 (ko) Ｎｏｓ 저해작용을 가진 방향족 아민 유도체
US8895552B2 (en) Cyclic amide derivative
CN111757770B (zh) 作为gpr40激动剂的3-苯基-4-己炔酸衍生物
RU2008142528A (ru) Улучшенный кристаллический материал
CA2799556A1 (en) Compounds
TW201726651A (zh) ２，３，４，５－四氫吡啶－６－胺衍生物
WO2021012689A1 (zh) 一种苯基噻吩磺酰胺类化合物、药物组合物、其制备方法和应用
US20220298186A1 (en) Biaryl dialkyl phosphine oxide fpr2 agonists
CA2976889A1 (en) Quinuclidine derivative
Saravanan et al. Synthesis and characterization of 5-(2-nitro-1-arylpropyl)-4-aryl-1, 2, 3-selenadiazoles
CA2828764A1 (en) Anti-amyloid compounds and methods
JPH10231245A (ja) アルキルアミン誘導体

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131009